<DOC>
	<DOC>NCT00046800</DOC>
	<brief_summary>The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.</brief_summary>
	<brief_title>Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<criteria>Confirmed relapsed ovarian cancer. Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan). One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin. At least three weeks since prior chemotherapy and recovery from any related toxicities. At least four weeks since prior radiotherapy and recovery from any related toxicities.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Ovarian Cancer</keyword>
</DOC>